Handok (002390) - Total Liabilities

Latest as of September 2025: ₩536.54 Billion KRW ≈ $363.60 Million USD

Based on the latest financial reports, Handok (002390) has total liabilities worth ₩536.54 Billion KRW (≈ $363.60 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 002390 operating cash flow to assess how effectively this company generates cash.

Handok - Total Liabilities Trend (2011–2024)

This chart illustrates how Handok's total liabilities have evolved over time, based on quarterly financial data. Check 002390 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Handok Competitors by Total Liabilities

The table below lists competitors of Handok ranked by their total liabilities.

Company Country Total Liabilities
American Well Corp
NYSE:AMWL
USA $76.00 Million
Guizhou Zhongyida Co Ltd
SHG:900906
China $899.58 Million
Pluristem
TA:PSTI
Israel ILA38.98 Million
DeviceENG.CO.Ltd
KQ:187870
Korea ₩81.14 Billion
Sree Rayalaseema Hi-Strength Hypo Limited
NSE:SRHHYPOLTD
India Rs1.47 Billion
Daios Plastics S.A.
AT:DAIOS
Greece €107.87 Million
Big Ridge Gold Corp
V:BRAU
Canada CA$986.91K
Sokoman Minerals Corp
V:SIC
Canada CA$241.75K

Liability Composition Analysis (2011–2024)

This chart breaks down Handok's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Handok market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.78 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 2.02 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.67 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Handok's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Handok (2011–2024)

The table below shows the annual total liabilities of Handok from 2011 to 2024.

Year Total Liabilities Change
2024-12-31 ₩499.49 Billion
≈ $338.50 Million
+11.07%
2023-12-31 ₩449.71 Billion
≈ $304.76 Million
-8.08%
2022-12-31 ₩489.25 Billion
≈ $331.56 Million
+6.92%
2021-12-31 ₩457.57 Billion
≈ $310.09 Million
+4.69%
2020-12-31 ₩437.08 Billion
≈ $296.20 Million
+8.01%
2019-12-31 ₩404.67 Billion
≈ $274.24 Million
+19.29%
2018-12-31 ₩339.24 Billion
≈ $229.90 Million
-2.69%
2017-12-31 ₩348.63 Billion
≈ $236.26 Million
+4.51%
2016-12-31 ₩333.60 Billion
≈ $226.08 Million
+47.04%
2015-12-31 ₩226.88 Billion
≈ $153.75 Million
+9.23%
2014-12-31 ₩207.71 Billion
≈ $140.76 Million
+15.88%
2013-12-31 ₩179.25 Billion
≈ $121.48 Million
+20.19%
2012-12-31 ₩149.14 Billion
≈ $101.07 Million
+14.83%
2011-12-31 ₩129.88 Billion
≈ $88.02 Million
--

About Handok

KO:002390 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$90.77 Million
₩133.94 Billion KRW
Market Cap Rank
#19561 Global
#1100 in Korea
Share Price
₩10310.00
Change (1 day)
-1.81%
52-Week Range
₩10020.00 - ₩12400.00
All Time High
₩38942.94
About

HANDOK Inc. operates as a pharmaceutical company. The company provides prescription and OTC drugs; medical devices, such as blood pressure monitors, cholesterol monitoring systems, insulin pumps, self-monitoring system of blood glucose, and blood glucose monitoring system; in vitro diagnostic medical devices; as well as life science products. It also offers healthcare products comprising food sup… Read more